-
Development of pre-eclampsia within 4 weeks of sFlt-1/PlGF ratio > 38: comparison of performance at 31-34 vs 35-37 weeks' gestation.
Dragan I, Wright D, Fiolna M, Leipold G, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:209-212. pdf -
Competing-risks model in screening for pre-eclampsia in twin pregnancy according to maternal factors and biomarkers at 11-13 weeks' gestation.
Francisco C, Wright D, Benkő Z, Syngelaki A, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;50:589-595. pdf -
ASPRE trial: performance of screening for preterm pre-eclampsia.
Rolnik DL, Wright D, Poon LCY, Syngelaki A, O'Gorman N, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;50:492-495. pdf -
Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia.
Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Meiri H, Gizurarson S, Maclagan K, Nicolaides KH.
N Engl J Med 2017;377:613-622. pdf -
Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia.
Wright D, Poon LC, Rolnik DL, Syngelaki A, Delgado JL, Vojtassakova D, de Alvarado M, Kapeti E, Rehal A, Pazos A, Carbone IF, Dutemeyer V, Plasencia W, Papantoniou N, Nicolaides KH.
Am J Obstet Gynecol 2017;217:685.e1-685.e5. pdf -
Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history.
Poon LC, Wright D, Rolnik DL, Syngelaki A, Delgado JL, Tsokaki T, Leipold G, Akolekar R, Shearing S, De Stefani L, Jani JC, Plasencia W, Evangelinakis N, Gonzalez-Vanegas O, Persico N, Nicolaides KH.
Am J Obstet Gynecol 2017;217:585.e1-585.e5. pdf -
Impaired placentation in women with chronic hypertension that develop preeclampsia.
Panaitescu AM, Akolekar R, Kametas N, Syngelaki A, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;50:496-500. pdf -
A study protocol for the prospective validation study: Screening programme for pre-eclampsia (SPREE)
Tan MY, Koutoulas L, Wright D, Nicolaides KH, Poon LC.
Ultrasound Obstet Gynecol 2017;50:175-179. pdf -
Multicenter screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks' gestation: comparison to NICE guidelines and ACOG recommendations.
O' Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, de Alvarado M, Carbone IF, Dutemeyer V, Fiolna M, Frick A, Karagiotis N, Mastrodima S, de Paco Matallana C, Papaioannou G, Pazos A, Plasencia W, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:756-760. pdf -
Accuracy of competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation.
O'Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, Wright A, Akolekar R, Cicero S, Janga D, Jani J, Molina FS, de Paco Matallana C, Papantoniou N, Persico N, Plasencia W, Singh M, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:751-755. pdf -
Comparison of screening for preeclampsia at 31-34 weeks' gestation by the sFLT to PLGF ratio and a method combining maternal factors with sFLT-1 and PLGF.
Tan MY, Wright D, Koutoulas L, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:201-208. -
Screening for pre-eclampsia using sFlt-1/PlGF ratio cut-off of 38 at 30-37 weeks' gestation.
Dragan I, Georgiou T, Prodan N, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:73-77. pdf -
Development of preeclampsia within four weeks of sFLT to PLGF ratio >38: Comparison of performance at 31-34 versus 35-37 weeks' gestation.
Dragan I, Wright D, Fiolna M, Leipold G, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:209-12. pdf -
Comparison of screening for pre-eclampsia at 31-34 weeks' gestation by sFlt-1/PlGF ratio and a method combining maternal factors with sFlt-1 and PlGF.
Tan MY, Wright D, Koutoulas L, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:201-8. pdf -
Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE)
O'Gorman N, Wright D, Rolnik DL, Nicolaides KH, Poon LC.
BMJ Open 2016;6:e011801. pdf -
Competing-risks model in screening for pre-eclampsia by maternal factors and biomarkers at 35-37 weeks' gestation.
Andrietti S, Silva M, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;48:72-9. pdf -
Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
Khalil A, Maiz N, Garcia-Mandujano R, Penco JM, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:324-31. pdf -
Biophysical and biochemical markers at 35-37 weeks' gestation in the prediction of adverse perinatal outcome.
Valiño N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:203-9. pdf -
Biophysical and biochemical markers at 30-34 weeks' gestation in the prediction of adverse perinatal outcome.
Valino N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2016;47:194-202. pdf -
Inverted Pyramid of Care.
Sonek JD, Kagan KO, Nicolaides KH.
Clin Lab Med 2016;36:305-17. pdf